Exelixis (NASDAQ:EXEL)‘s stock had its “hold” rating reissued by analysts at Oppenheimer in a research note issued on Wednesday.

EXEL has been the subject of a number of other reports. Zacks Investment Research raised Exelixis from a “hold” rating to a “buy” rating and set a $29.00 price objective for the company in a report on Tuesday, October 10th. Royal Bank of Canada boosted their price objective on Exelixis from $33.00 to $39.00 and gave the stock an “outperform” rating in a report on Tuesday, October 17th. Needham & Company LLC reissued a “buy” rating and set a $30.00 price objective on shares of Exelixis in a report on Monday, October 2nd. TheStreet raised Exelixis from a “c+” rating to a “b-” rating in a report on Wednesday, October 18th. Finally, SunTrust Banks reissued a “buy” rating and set a $38.00 price objective on shares of Exelixis in a report on Thursday, December 21st. Six investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $32.13.

Shares of Exelixis (NASDAQ:EXEL) traded down $2.45 on Wednesday, reaching $27.20. The company’s stock had a trading volume of 5,679,631 shares, compared to its average volume of 2,590,000. The company has a market cap of $8,050.00, a price-to-earnings ratio of 55.51, a P/E/G ratio of 0.91 and a beta of 1.88. Exelixis has a 1 year low of $16.72 and a 1 year high of $32.50.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported $0.26 EPS for the quarter, topping analysts’ consensus estimates of $0.08 by $0.18. The firm had revenue of $152.50 million during the quarter, compared to analyst estimates of $104.91 million. Exelixis had a return on equity of 105.47% and a net margin of 36.80%. The company’s revenue for the quarter was up 145.2% on a year-over-year basis. During the same period in the previous year, the company posted ($0.04) EPS. research analysts forecast that Exelixis will post 0.49 earnings per share for the current year.

In other news, Director Alan M. Garber sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $30.30, for a total value of $454,500.00. Following the completion of the transaction, the director now directly owns 64,829 shares of the company’s stock, valued at $1,964,318.70. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 5.10% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the company. Mark Sheptoff Financial Planning LLC bought a new position in shares of Exelixis in the third quarter valued at approximately $120,000. Fisher Asset Management LLC bought a new position in shares of Exelixis in the third quarter valued at approximately $213,000. Caxton Associates LP purchased a new position in Exelixis in the second quarter valued at approximately $227,000. Raymond James Financial Services Advisors Inc. purchased a new position in Exelixis in the third quarter valued at approximately $236,000. Finally, CIBC Asset Management Inc purchased a new position in Exelixis in the third quarter valued at approximately $238,000. 80.84% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Oppenheimer Reaffirms Hold Rating for Exelixis (EXEL)” was first posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2018/01/17/oppenheimer-reaffirms-hold-rating-for-exelixis-exel.html.

About Exelixis

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Analyst Recommendations for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.